look forward first tripl
combin phase data ye
ep beat lower opex
report non-gaap ep surpass consensu total
cystic fibrosi cf product sale in-lin consensu non-
 sg expens consensu
baselin cf busi track well investor focus phase
result first tripl combin lower ep estim
beyond due increas tax rate account rule chang interest expens
combin orkambi symdeko sale gener in-lin consensu
repres growth q/q homozyg patient strong
uptak symdeko off-set declin sale orkambi due patient switch
kalydeco sale in-lin consensu launch symdeko
continu strong manag comment homozyg
mutat market yet fulli penetr expect peak share achiev
hand continu monitor progress reimburs
orkambi uk franc sale continu grow countri
reimburs alreadi secur
despit signific progress clinic develop tripl combin
commit invest field phase studi once-daili
deuter kalydeco patient gate mutat initi beyond cf
continu advanc multipl pipelin asset fda recent lift clinic
hold sickl cell diseas scd studi expect start
expect preliminari data scd/ beta thalassemia program phase data
pain caus small fiber neuropathi expect earli small
molecul corrector treatment antitrypsin defici slate enter
clinic cash balanc coupl fast grow cash flow
believ continu invest intern pipelin well scout extern
opportun reiter buy vrtx lead franchis cf
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
posit view believ
remain leader cystic fibrosi treatment
multipl posit readout next-gener cf
tripl combin allow penetr
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base probability-adjust npv analysi
cash flow use wacc deriv follow valu
kalydeco orkambi tez/iva tripl combin homozyg
patient tripl combin heterozyg patient
inclus net cash
downsid risk price object slower expect launch orkambi
lower price increment price pressur failur phase trial tripl
combin addit pipelin setback upsid risk quicker
expect uptak orkambi better expect pricing/compli orkambi
quicker develop tripl combo heterozyg patient
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
